These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 30295237)

  • 1. [Primary Prophylatic Effect of Voriconazole Against Invasive Infection of Pulmonary Aspergillosis during Remission-Induction Chemotherapy for Acute Myeloid Leukemia].
    Gong BF; Lin D; Wei H; Wang Y; Liu BC; Zhou CL; Liu KQ; Wei SN; Zhang GJ; Liu YT; Gong XY; Li Y; Zhao XL; Qiu SW; Gu RX; Mi YC; Wang JX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct; 26(5):1269-1274. PubMed ID: 30295237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Breakthrough of invasive fungal disease with posaconazole as primary prophylaxis after induction chemotherapy for acute myeloid leukemia].
    Pei RZ; Lu Y; Zhang PS; Liu XH; Chen D; Du XH; Sha KY; Li SY; Cao JJ; Chen LG; Zhuang XX; Tang SH
    Zhonghua Nei Ke Za Zhi; 2020 Mar; 59(3):213-217. PubMed ID: 32146748
    [No Abstract]   [Full Text] [Related]  

  • 3. [Primary antifungal prophylaxis with posaconazole plays a pivotal role during chemotherapy of acute myeloid leukemia].
    Gong BF; Liu YT; Zhang GJ; Wei SN; Li Y; Liu KQ; Gong XY; Zhao XL; Qiu SW; Gu RX; Lin D; Wei H; Zhou CL; Liu BC; Wang Y; Mi YC; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):528-531. PubMed ID: 28655098
    [No Abstract]   [Full Text] [Related]  

  • 4. Posaconazole versus voriconazole as antifungal prophylaxis during induction therapy for acute myelogenous leukemia or myelodysplastic syndrome.
    Phillips K; Cirrone F; Ahuja T; Siegfried J; Papadopoulos J
    J Oncol Pharm Pract; 2019 Mar; 25(2):398-403. PubMed ID: 30319061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Posaconazole for primary antifungal prophylaxis in patients with acute myeloid leukaemia or myelodysplastic syndrome during remission induction chemotherapy: a single-centre retrospective study in Korea and clinical considerations.
    Cho SY; Lee DG; Choi SM; Choi JK; Lee HJ; Kim SH; Park SH; Choi JH; Yoo JH; Kim YJ; Kim HJ; Min WS
    Mycoses; 2015 Sep; 58(9):565-71. PubMed ID: 26214656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy.
    Park H; Youk J; Shin DY; Hong J; Kim I; Kim NJ; Lee JO; Bang SM; Yoon SS; Park WB; Koh Y
    BMC Cancer; 2019 Apr; 19(1):358. PubMed ID: 30991992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased invasive fungal disease but no impact on overall survival by posaconazole compared to fluconazole prophylaxis: a retrospective cohort study in patients receiving induction therapy for acute myeloid leukaemia/myelodysplastic syndromes.
    Dahlén T; Kalin M; Cederlund K; Nordlander A; Björkholm M; Ljungman P; Blennow O
    Eur J Haematol; 2016 Feb; 96(2):175-80. PubMed ID: 25880378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemia.
    Al-Badriyeh D; Slavin M; Liew D; Thursky K; Downey M; Grigg A; Bajel A; Stewart K; Kong DC
    J Antimicrob Chemother; 2010 May; 65(5):1052-61. PubMed ID: 20237074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of breakthrough fungal infections on isavuconazole prophylaxis compared to posaconazole and voriconazole.
    Scott SA; Perry C; Mahmoudjafari Z; Martin GA; Boyd S; Thompson J; Thomas B
    Transpl Infect Dis; 2023 Apr; 25(2):e14045. PubMed ID: 36856447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacoeconomic evaluation of fluconazole, posaconazole and voriconazole for antifungal prophylaxis in patients with acute myeloid leukaemia undergoing first consolidation chemotherapy.
    Heng SC; Slavin MA; Al-Badriyeh D; Kirsa S; Seymour JF; Grigg A; Thursky K; Bajel A; Nation RL; Kong DC
    J Antimicrob Chemother; 2013 Jul; 68(7):1669-78. PubMed ID: 23485723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML).
    Vehreschild JJ; Böhme A; Buchheidt D; Arenz D; Harnischmacher U; Heussel CP; Ullmann AJ; Mousset S; Hummel M; Frommolt P; Wassmer G; Drzisga I; Cornely OA
    J Infect; 2007 Nov; 55(5):445-9. PubMed ID: 17822770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-benefit Analysis of Posaconazole Versus Fluconazole or Itraconazole as a Primary Antifungal Prophylaxis in High-risk Hematologic Patients: A Propensity Score-matched Analysis.
    Cho SY; Lee DG; Choi JK; Lee HJ; Kim SH; Park SH; Choi SM; Choi JH; Yoo JH; Kim YJ; Kim HJ; Min WS; Back H; Kang S; Lee EK
    Clin Ther; 2015 Sep; 37(9):2019-27. PubMed ID: 26188835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence density of invasive fungal infections during primary antifungal prophylaxis in newly diagnosed acute myeloid leukemia patients in a tertiary cancer center, 2009 to 2011.
    Gomes MZ; Mulanovich VE; Jiang Y; Lewis RE; Kontoyiannis DP
    Antimicrob Agents Chemother; 2014; 58(2):865-73. PubMed ID: 24277033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of invasive fungal diseases between patients with acute myeloid leukemia receiving posaconazole prophylaxis and those not receiving prophylaxis: A single-center, observational, case-control study in South Korea.
    Yang E; Choi EJ; Park HS; Lee SO; Choi SH; Kim YS; Lee JH; Lee JH; Lee KH; Kim SH
    Medicine (Baltimore); 2021 May; 100(20):e25448. PubMed ID: 34011022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of antifungal prophylaxis with oral suspension posaconazole during induction chemotherapy of acute myeloid leukemia.
    Schrenk KG; Schnetzke U; Stegemann K; von Lilienfeld-Toal M; Hochhaus A; Scholl S
    J Cancer Res Clin Oncol; 2015 Sep; 141(9):1661-8. PubMed ID: 25800622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aerosolised liposomal amphotericin B to prevent aspergillosis in acute myeloid leukaemia: Efficacy and cost effectiveness in real-life.
    Chong GL; Broekman F; Polinder S; Doorduijn JK; Lugtenburg PJ; Verbon A; Cornelissen JJ; Rijnders BJ
    Int J Antimicrob Agents; 2015 Jul; 46(1):82-7. PubMed ID: 25956843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Voriconazole prophylaxis in leukemic patients: A retrospective single-center study.
    Bui V; Walker SA; Elligsen M; Vyas A; Kiss A; Palmay L
    J Oncol Pharm Pract; 2020 Jun; 26(4):873-881. PubMed ID: 31566111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole.
    Barreto JN; Beach CL; Wolf RC; Merten JA; Tosh PK; Wilson JW; Hogan WJ; Litzow MR
    Am J Hematol; 2013 Apr; 88(4):283-8. PubMed ID: 23460251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breakthrough invasive aspergillosis and diagnostic accuracy of serum galactomannan enzyme immune assay during acute myeloid leukemia induction chemotherapy with posaconazole prophylaxis.
    Calmettes C; Gabriel F; Blanchard E; Servant V; Bouchet S; Kabore N; Forcade E; Leroyer C; Bidet A; Latrabe V; Leguay T; Vigouroux S; Tabrizi R; Breilh D; Accoceberry I; de Lara MT; Pigneux A; Milpied N; Dumas PY
    Oncotarget; 2018 Jun; 9(42):26724-26736. PubMed ID: 29928481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort.
    Vehreschild JJ; Rüping MJ; Wisplinghoff H; Farowski F; Steinbach A; Sims R; Stollorz A; Kreuzer KA; Hallek M; Bangard C; Cornely OA
    J Antimicrob Chemother; 2010 Jul; 65(7):1466-71. PubMed ID: 20410061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.